Federal Right to Try: Where Is It Going?

Area of Science:

• Medical Law and Ethics
• Pharmaceutical Policy
• Patient Advocacy

Background:

• The federal right-to-try law has sparked debate among policymakers, bioethicists, and patient advocates.
• Key issues include patient autonomy, government regulation of unapproved drugs, and medical paternalism.

Purpose of the Study:

• To analyze the history and arguments surrounding the right-to-try movement.
• To evaluate the potential consequences of federal right-to-try legislation on patient access to investigational therapies.

Main Methods:

• Review of the historical development of the right-to-try movement.
• Analysis of arguments from proponents and opponents of right-to-try laws.
• Examination of potential regulatory and commercial implications.

Main Results:

• The right-to-try pathway may not substantially enhance patient access to investigational products.
• Companies might leverage right-to-try laws to market drugs, exploiting cost provisions due to weak enforcement mechanisms.

Conclusions:

• Federal right-to-try legislation presents complex ethical and regulatory challenges.
• The effectiveness and potential for misuse of these laws warrant careful consideration and monitoring.